FUJIFILM
Value from Innovation

NEVER STOP

Earnings of Q2 FY2020

FUJIFILM Holdings Corporation

November 10, 2020

FORWARD-LOOKING STATEMENTS

Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors.



In FUJIFILM Holdings' performance for the first half of FY2020, the fiscal year ending March 2021, revenue fell 11.9% year-on-year to ¥997.4 billion, and operating income was down 38.6% to ¥56.5 billion yen.

The negative impact of COVID-19 was ¥152 billion on revenue and ¥46 billion yen on operating income.
The situation in the global economy remains severe due to the expanding impact of COVID-19, but there are signs of a gradual recovery as individual countries make moves to balance the resumption of economic activity with measures to curb the further spread of the virus.

The pace of decline in business performance is shrinking and we have confirmed a path to recovery in the second quarter.

Net income attributable to FUJIFILM Holdings increased by double digits year-on-year to ¥67.6 billion yen. This was helped by gains on equity securities and by the improvement of net income attributable to non-controlling interests due to Fuji Xerox being made a wholly-owned subsidiary.

In terms of the full-year forecast, given the favorable performance of the bio CDMO business, we have revised our revenue forecast upward by ¥10 billion from the previous forecast to ¥2,210 billion. The Bio CDMO business is expected to achieve its ¥100 billion revenue target a year ahead of schedule.

The forecast for operating income has been revised upward by ¥3 billion to ¥143 billion. Healthcare's operating income is expected to increase due to sales growth in the bio CDMO business and a reduction in fixed costs.

We have revised our net income attributable to FUJIFILM Holdings upward by ¥5 billion to ¥125 billion.



The performance for the first half is as shown here.



Revenue and operating income of each segment are as shown here.



First, we will look at an overview of the Healthcare & Material Solutions segment. Looking at the Healthcare field, in the medical systems business, in addition to the impacts of COVID-19, including voluntary restraint from sales visits to hospitals and delays in sales talks, the rebound effect of last-minute-rush demand prior to the enforcement of the consumption tax increase last year in Japan caused revenue overall to fall, but sales of portable ultrasonic diagnostic equipment and mobile X-ray equipment for pneumonia diagnosis increased.

In the bio CDMO business, the consolidation of the business base in Denmark acquired in August last year and the strong performance in the contract process development and manufacture business for biopharmaceuticals contributed to a major increase in revenue.

In the regenerative medicine business, revenue increased thanks to brisk sales of medium cultures for bio production by our American subsidiary, FUJIFILM Irvine Scientific.

In the Materials Solutions field, revenue in the electronic materials business increased due to strong sales of semiconductor process materials accompanying increased demand for data center servers, against the backdrop of expansion in work-from home.
In the graphic system business, in addition to the decrease in demand for printing plates, the demand for printing posters and leaflets decreased due to the self-restraint/cancellation of events due to the impact of COVID-19, resulting in a decrease in revenue.
The Healthcare & Materials Solutions segment recorded a decline in revenue overall, but revenue was up in the Healthcare field thanks to strong revenue performances in the bio CDMO and regenerative medicine businesses. Within the Materials Solutions field, by steadily capturing increased demands for PCs, monitors, and tablets, caused by the expansion of work-from-home and remote learning, we increased revenue in highly functional materials.

Operating income rose because increased revenue in the healthcare field and highly functional materials area and extensive cost-cutting efforts compensated the impacts of COVID-19 pandemic.

Moving on to an overview of the Document Solutions segment.

In the office products and printers business, the decline in office operations due to the impact of COVID-19, among other factors, caused a drop in print volumes, but MFP sales volumes increased over the same period last fiscal year in Japan, China, and other regions.

Also, due to the spread of work-from-home, we saw an expansion of demand for services such as the Netprint® service using multi-copiers installed in Seven-Eleven stores across Japan.

In the production services business, investment was curtailed by the sense of uncertainty about the future brought about by COVID-19, resulting in a decline in sales volumes.

In the solutions and services business, revenue was down overall due to the impact of COVID-19, but sales of products to support remote work increased, including “beat,” which offers a robust security network environment, and paperless fax solutions that allow faxes received at the office to be checked at home.

In addition to the impact of COVID-19, the Document Solutions segment also suffered negative forex impacts due to the depreciation of Asian currencies, resulting in a decline in revenue.

Operating income was down due to revenue declines caused by the impact of COVID-19, but thanks to thorough efforts in operational reforms undertaken before the pandemic, such as operational productivity improvements, reductions in product development timeframes, and cost-cutting, the segment has lowered its break-even point and formed a business structure that enables profits to be made even in a severe business climate.



Moving on to the performance of the Imaging Solutions segment.

In the photo imaging business, in addition to the decline in demand for color paper, stay-at-home orders and temporary store closures due to the impact of COVID-19 resulted in a fall in revenue, but sales volumes of *instax* cameras in the second quarter, primarily the *instax mini 11*, were up on the same quarter last year, and sales of instant photo systems are trending toward recovery.

In the electronic imaging business, besides the severe climate in the digital camera market overall, the COVID-19 pandemic, which caused fewer opportunities to take photographs as a result of temporary store closures and restrictions on outings, depressed revenue. However, sales of *FUJIFILM X-T4*, which has been acclaimed for its high-speed auto-focus and excellent video features, and other models have been brisk.

In the optical device business, revenue fell due to such factors as a decline in sales of lenses for broadcasting and cinema, because of the cancellation of events, and lower sales of vehicle-mounted lenses as a result of a worldwide decline in demand for automobiles.

The Imaging Solutions segment recorded a year-on-year decline in revenue primarily due to the impact of COVID-19, but it is recovering, with sales volumes of *instax* cameras increasing year-on-year, for example.

Operating income was down, but if COVID-19 impacts are excluded, the segment secured income of a similar level to last year.



Now, let’s take a look at the Balance Sheet.

Assets as of the end of September 2020 totaled ¥3,308.2 billion. This was a decrease of ¥13.5 billion from the end of March 2020, due to such factors as a decline in notes and accounts receivables.

Liabilities fell by ¥77.7 billion to ¥1,250.2 billion, due to falls in short-term and long-term debt, and shareholders’ equity increased by ¥61.2 billion to ¥2,014.5 billion.



Finally, let’s move on to cash flow.

Net cash provided by operating activities totaled ¥194.6 billion, an increase of ¥37.0 billion year-on-year due to a decrease in notes and accounts receivable, among other factors.

Net cash used in investing activities amounted to ¥62.2 billion, mainly due to capital expenditure.

As a result, free cash flow without acquisitions of businesses and similar was ¥130.2 billion.

In FY2020, given the uncertainty of the economic environment, we will exercise caution in the allocation of cash to capital expenditures and other investments, setting priorities after careful examination of growth opportunities and investment efficiency. Also, by introducing ROIC and CCC to our business management, we will enhance our cash generation capacity and balance sheet management to maintain a sound financial position.

Regarding dividends, we will issue an interim dividend of ¥47.5 per share. An annual dividend of ¥95 per share is planned.

This concludes the overview of the company’s performance in the first half of the year ending March 2021.



Moving on to the forecast for FY2020, ending March 2021.



In our consolidated financial forecast for FY2020, as I mentioned at the beginning, thanks to the strong performance of the bio CDMO business and other factors such as a reduction in fixed costs, we have revised our revenue forecast upward by ¥10 billion and operating income forecast by ¥3 billion.

In addition, income before income taxes will be revised upward by ¥5 billion including gains on equity securities, and net income attributable to FUJIFILM Holdings will be revised by ¥5 billion. Despite the strong impacts of the COVID-19, we will maintain ¥125 billion, which is the same as that of last year.



Finally, I will explain the key points of our results for the first half of FY2020 and our forecasts for the second half of the fiscal year. The first half results progressed as forecast in each segment.

For the company overall, on the assumption that revenue would gradually recover after bottoming out in the first quarter, we forecast that whole-company Q4 revenue would exceed that of the fourth quarter of FY2018, which was not impacted by COVID-19, marking a return to pre-COVID-19 levels.

Compared with the fourth quarter of FY2019, which was impacted by the pandemic, we are forecasting a year-on-year increase in revenue in all segments.

Healthcare will maintain its revenue growth, driven by the bio CDMO business and others.

In Materials, electronic materials will continue to perform well, but demand is expected to settle down in display materials, industrial equipment materials for monitors for work-from-home use, and other areas.

In Documents, with the spread of remote work and the like, office print volumes are anticipated to recover to about 95% of pre-COVID-19 levels in Japan and to about 90% in our overseas sales territory of the Asia-Pacific.

In response to the decline in print volumes, we will accelerate our efforts in Solutions & Services to expand revenue.

Imaging is recovering steadily, with second-quarter sales of *instax* cameras up year-on-year, among other factors. We will continue this trend in the third quarter and beyond.

FUJIFILM
Value from Innovation

NEVER STOP

Earnings for Q FY2020

Appendices

FUJIFILM

Analysis of Operating Income Change (H1, against H1 FY2019)



Document one-time cost

- H1 FY2019: Structural reforms expenses, etc.	+4.5
- H1 FY2020: Rebranding expenses	-2.9
- H1 FY2020: Structure strengthening expenses	-3.6

Analysis of Changes in Operating Income (Full-year forecast year-on-year)



Earnings for Q2 FY2020

(Billions of yen)

	Q2			H1		
	FY2019	FY2020	Change	FY2019	FY2020	Change
Revenue	596.8 100.0%	541.1 100.0%	(55.7) -9.3%	1,132.1 100.0%	997.4 100.0%	(134.7) -11.9%
Operating Income	54.9 9.2%	36.1 6.7%	(18.8) -34.3%	92.0 8.1%	56.5 5.7%	(35.5) -38.6%
Income before Income Taxes	71.1 11.9%	57.4 10.6%	(13.7) -19.4%	97.5 8.6%	99.6 10.0%	2.1 +2.1%
Net Income Attributable to FUJIFILM Holdings	46.4 7.8%	40.1 7.4%	(6.3) -13.7%	61.1 5.4%	67.6 6.8%	6.5 +10.6%
Exchange Rates US$/¥ €/¥	¥107 ¥119	¥106 ¥124	(¥1) ¥5	¥109 ¥121	¥107 ¥122	(¥2) ¥1

Other factors of increase/decrease (Q2/H1 FY2020 against Q2/H1 FY2019)
Operating income of raw materials: +0.1 billion yen / +1.1 billion yen

Earning for Q2/H1 FY2020

(Billions of yen)

Revenue	Q2				H1			
	FY2019	FY2020	Change		FY2019	FY2020	Change	
Healthcare	126.3	135.2	8.9	(+7.0%)	230.4	243.1	12.7	(+5.5%)
Healthcare & Material Solutions	265.1	256.2	(8.9)	(-3.3%)	492.7	473.3	(19.4)	(-3.9%)
Document Solutions	252.2	220.8	(31.4)	(-12.5%)	485.3	410.2	(75.1)	(-15.5%)
Imaging Solutions	79.5	64.1	(15.4)	(-19.4%)	154.1	113.9	(40.2)	(-26.1%)
Total	596.8	541.1	(55.7)	(-9.3%)	1,132.1	997.4	(134.7)	(-11.9%)

Note: After elimination of intersegment transactions

(Billions of yen)

Operating Income [Operating Margin]	Q2				H1			
	FY2019	FY2020	Change		FY2019	FY2020	Change	
Healthcare	5.8 [4.6%]	14.3 [10.5%]	8.5	(2.4 times)	11.1 [4.8%]	18.7 [7.7%]	7.6	(+67.4%)
Healthcare & Material Solutions	26.1 [9.9%]	27.8 [10.8%]	1.7	(+6.2%)	45.0 [9.1%]	45.8 [9.7%]	0.8	(+1.6%)
Document Solutions	33.2 [13.2%]	15.4 [7.0%]	(17.8)	(-53.6%)	54.9 [11.3%]	28.3 [6.9%]	(26.6)	(-48.4%)
Imaging Solutions	5.6 [7.1%]	0.9 [1.4%]	(4.7)	(-83.9%)	10.1 [6.6%]	(2.1) [-1.9%]	(12.2)	-
Corporate Expenses & Eliminations	(10.0)	(8.0)	2.0	-	(18.0)	(15.5)	2.5	-
Total	54.9 [9.2%]	36.1 [6.7%]	(18.8)	(-34.3%)	92.0 [8.1%]	56.5 [5.7%]	(35.5)	(-38.6%)

Earning for Q2/H1 FY2020

Healthcare & Material Solutions

(Billions of yen)

Revenue	Q2						H1					
	FY2019	FY2020	Change		Constant-currency basis		FY2019	FY2020	Change		Constant-currency basis	
Healthcare	126.3	135.2	8.9	(+7.0%)	9.6	(+7.6%)	230.4	243.1	12.7	(+5.5%)	15.6	(+6.8%)
Display Materials	25.4	23.5	(1.9)	(-7.7%)	(1.9)	(-7.7%)	46.2	44.2	(2.0)	(-4.3%)	(2.0)	(-4.3%)
Industrial Products Electronic Materials Fine Chemical	44.0	46.3	2.3	(+5.0%)	2.5	(+5.3%)	85.2	92.4	7.2	(+8.3%)	8.1	(+9.4%)
Highly Functional Materials	69.4	69.8	0.4	(+0.3%)	0.6	(+0.6%)	131.4	136.6	5.2	(+3.9%)	6.1	(+4.6%)
Recording Media	13.5	6.9	(6.6)	(-48.4%)	(6.5)	(-47.9%)	23.2	12.4	(10.8)	(-46.4%)	(10.6)	(-45.5%)
Graphic Systems/Inkjet	55.5	44.1	(11.4)	(-20.5%)	(11.2)	(-20.3%)	107.0	80.6	(26.4)	(-24.6%)	(25.5)	(-23.8%)
Others	0.4	0.2	(0.2)		(0.3)		0.7	0.6	(0.1)		0.0	
Total	265.1	256.2	(8.9)	(-3.3%)	(7.8)	(-2.9%)	492.7	473.3	(19.4)	(-3.9%)	(14.4)	(-2.9%)

Note: After elimination of intersegment transactions

(Billions of yen)

Operating Income [Operating Margin]	Q2						H1					
	FY2019	FY2020	Change		Constant-currency basis		FY2019	FY2020	Change		Constant-currency basis	
Healthcare	5.8 [4.6%]	14.3 [10.5%]	8.5	(2.4 times)	9.7	(2.6 times)	11.1 [4.8%]	18.7 [7.7%]	7.6	(+67.4%)	9.3	(+82.7%)
Healthcare & Material Solutions	26.1 [9.9%]	27.8 [10.8%]	1.7	(+6.2%)	3.1	(+11.4%)	45.0 [9.1%]	45.8 [9.7%]	0.8	(+1.6%)	3.1	(+6.7%)

Changes in Quarterly Earnings by Operating Segment

Healthcare & Material Solutions

(Billions of yen)



Earnings for Q2/H1 FY2020

Document Solutions

(Billions of yen)

Revenue	Q2						H1					
	FY2019	FY2020	Change		Constant-currency basis		FY2019	FY2020	Change		Constant-currency basis	
Office Printers	31.4	22.7	(8.7)	(-27.5%)	(8.6)	(-27.3%)	60.2	46.1	(14.1)	(-23.3%)	(13.5)	(-22.3%)
Office Products & Printers	139.4	124.4	(15.0)	(-10.8%)	(14.9)	(-10.7%)	273.1	232.8	(40.3)	(-14.8%)	(38.0)	(-13.9%)
Production Services	31.5	26.8	(4.7)	(-15.2%)	(4.7)	(-15.3%)	58.8	47.8	(11.0)	(-18.8%)	(10.4)	(-17.8%)
Solutions & Services	74.3	62.9	(11.4)	(-15.4%)	(11.7)	(-15.8%)	136.8	114.6	(22.2)	(-16.3%)	(21.4)	(-15.6%)
Others	7.0	6.7	(0.3)		(0.5)		16.6	15.0	(1.6)		(1.5)	
Total	252.2	220.8	(31.4)	(-12.5%)	(31.8)	(-12.6%)	485.3	410.2	(75.1)	(-15.5%)	(71.3)	(-14.7%)

Note: After elimination of intersegment transactions

(Billions of yen)

Operating Income [Operating Margin]	Q2						H1					
	FY2019	FY2020	Change		Constant-currency basis		FY2019	FY2020	Change		Constant-currency basis	
Document Solutions	33.2 [13.2%]	15.4 [7.0%]	(17.8)	(-53.6%)	(17.7)	(-53.3%)	54.9 [11.3%]	28.3 [6.9%]	(26.6)	(-48.4%)	(24.7)	(-44.9%)

Changes in Quarterly Earnings by Operating Segment

Document Solutions

(Billions of yen)



Earnings for Q2/H1 FY2020

Imaging Solutions

(Billions of yen)

Revenue	Q2						H1					
	FY2019	FY2020	Change		Constant-currency basis		FY2019	FY2020	Change		Constant-currency basis	
Photo Imaging	53.6	43.0	(10.6)	(-20.0%)	(10.4)	(-19.5%)	100.5	73.4	(27.1)	(-27.0%)	(26.0)	(-25.9%)
Electronic Imaging	17.4	15.6	(1.8)	(-10.0%)	(1.7)	(-9.8%)	37.0	30.8	(6.2)	(-16.5%)	(5.5)	(-14.7%)
Optical Devices	8.5	5.5	(3.0)	(-34.8%)	(3.0)	(-34.3%)	16.6	9.7	(6.9)	(-41.7%)	(6.8)	(-41.0%)
Optical Device & Electronic Imaging Products	25.9	21.1	(4.8)	(-18.1%)	(4.7)	(-17.9%)	53.6	40.5	(13.1)	(-24.3%)	(12.3)	(-22.9%)
Total	79.5	64.1	(15.4)	(-19.4%)	(15.1)	(-19.0%)	154.1	113.9	(40.2)	(-26.1%)	(38.3)	(-24.8%)

Note: After elimination of intersegment transactions

(Billions of yen)

Operating Income [Operating Margin]	Q2						H1					
	FY2019	FY2020	Change		Constant-currency basis		FY2019	FY2020	Change		Constant-currency basis	
Imaging Solutions	5.6 [7.1%]	0.9 [1.4%]	(4.7)	(-83.9%)	(4.9)	(-87.5%)	10.1 [6.6%]	-2.1 [-1.9%]	(12.2)	-	(11.7)	-

Changes in Quarterly Earnings by Operating Segment

Imaging Solutions

(Billions of yen)



Revenue by Geographical Area

(Billions of yen)

	FY2019 H1		FY2020 H1		Change	
	Ratio (%)		Ratio (%)			
Japan	43.5%	491.9	42.7%	426.1	(65.8)	(-13.4%)
The Americas	18.0%	203.8	18.7%	186.0	(17.8)	(-8.7%)
Europe	12.4%	139.9	11.4%	114.1	(25.8)	(-18.4%)
China	12.1%	137.5	14.0%	140.1	2.6	(+1.8%)
Asia and others	26.1%	296.5	27.2%	271.2	(25.3)	(-8.6%)
Overseas	56.5%	640.2	57.3%	571.3	(68.9)	(-10.8%)
Consolidated total	100.0%	1,132.1	100.0%	997.4	(134.7)	(-11.9%)

Capital Expenditure, Depreciation and Amortization

Capital Expenditure (H1)



Depreciation & Amortization (H1)



(Billions of yen)

	Q2			H1			Full year		
	FY2018	FY2019	FY2020	FY2018	FY2019	FY2020	FY2018	FY2019	FY2020 (forecast)
Healthcare & Material	11.5	16.1	15.4	18.8	26.6	26.3	50.5	58.2	
Document	2.7	3.0	4.9	4.7	4.6	6.9	11.7	13.4	
Imaging	2.1	3.7	2.1	5.1	5.8	4.2	10.6	12.5	
Corporate	0.3	0.6	0.2	0.4	0.8	0.5	2.6	1.6	
Capex *	16.6	23.4	22.6	29.0	37.8	37.9	75.4	85.7	95.0
Healthcare & Material	15.4	15.9	16.3	29.7	30.5	32.3	63.1	63.9	
Document	12.5	10.4	9.5	25.5	21.8	19.2	50.1	41.8	
Imaging	3.6	3.6	3.7	7.0	7.0	7.3	14.1	14.6	
Corporate	0.4	0.6	0.7	1.0	1.2	1.3	2.6	2.4	
Depreciation& Amortization	31.9	30.5	30.2	63.2	60.5	60.1	129.9	122.7	130.0
Depreciation *	16.7	17.1	16.6	33.4	33.4	33.1	70.9	68.6	

*Note: Figures do not include amounts for rental equipment handled by the Document Solutions segment and others.

Healthcare & Material
Document Solutions
Imaging Solutions
Corporate

R&D Expenses, SG&A Expenses

R&D Expenses (H1)



Healthcare & Material
Document Solutions
Imaging Solutions
Corporate

(Billions of yen)

	Q2		H1		Full Year	
	FY2019	FY2020	FY2020/3	FY2021/3	FY2019	FY2020 (forecast)
Healthcare & Material	17.6	17.1	34.8	33.2	69.5	
Document	12.8	12.7	25.8	24.3	50.7	
Imaging	2.8	2.1	5.5	4.6	10.1	
Corporate	7.5	6.1	13.6	12.3	27.6	
R&D Expenses	40.7	38.0	79.7	74.4	157.9	150.0
<ratio to revenue>	6.8%	7.0%	7.0%	7.5%	6.8%	6.8%
SG&A Expenses	149.6	135.7	301.9	266.3	610.0	
<ratio to revenue>	25.1%	25.1%	26.7%	26.6%	26.3%	

Exchange Rates, Raw Material Prices, and Number of Employees

Exchange Rates

(yen)

	FY2019				FY2020			
	Q1	Q2	H1	Full year	Q1	Q2	H1	Full year (forecast)
US$/¥	110	107	109	109	108	106	107	108
€/¥	123	119	121	121	119	124	122	120

Raw Material Prices (Average)

(¥1,000/kg)

	FY2019				FY2020			
	Q1	Q2	H1	Full year	Q1	Q2	H1	Full year (forecast)
Silver	53	57	55	57	55	78	63	64

Number of Employees

	2019.Sep	2019.Dec	2020.Mar	2020.Jun	2020.Sep
Consolidated Total	72,842	73,092	73,906	73,569	72,176

Financial Forecast for FY2020 by Operating Segments (As of November 10, 2020)

(Billions of yen)

Revenue	FY2019	FY2020 (previous forecast)	FY2020	Change from previous year		Change from previous forecast	COVID-19 impact
Healthcare	504.1	535.0	545.0	40.9	(+8.1%)	10.0	(40.0)
Material	520.1	485.0	485.0	(35.1)	(-6.7%)	0.0	(44.0)
Healthcare & Material Solutions	1,024.2	1,020.0	1,030.0	5.8	(+0.6%)	10.0	(84.0)
Document Solutions	958.3	895.0	895.0	(63.3)	(-6.6%)	0.0	(81.0)
Imaging Solutions	332.6	285.0	285.0	(47.6)	(-14.3%)	0.0	(55.0)
Total	2,315.1	2,200.0	2,210.0	(105.1)	(-4.5%)	10.0	(220.0)

Note: After elimination of intersegment transactions.

(Billions of yen)

Operating Income	FY2019	FY2020 (previous forecast)	FY2020	Change from previous year		Change from previous forecast	COVID-19 impact
Healthcare	33.1	42.0	45.0	11.9	(+36.1%)	3.0	(15.0)
Material	59.3	43.0	43.0	(16.3)	(-27.5%)	0.0	(14.0)
Healthcare & Material Solutions	92.4	85.0	88.0	(4.4)	(-4.8%)	3.0	(29.0)
Document Solutions	105.0	80.0	80.0	(25.0)	(-23.8%)	0.0	(25.0)
Imaging Solutions	25.1	10.0	10.0	(15.1)	(-60.1%)	0.0	(15.0)
Corporate Expenses & Eliminations	(35.9)	(35.0)	(35.0)	0.9	-	0.0	0.0
Total	186.6	140.0	143.0	(43.6)	(-23.4%)	3.0	(69.0)

Shareholder Returns

■ Dividends

Planning annual dividend for FY2020
of ¥95 per share, the same as FY2019



■ Share buybacks

We will buy back shares flexibly, in consideration of cash flow situation, according to changes in stock price

Pipeline (As of November 10, 2020)

Development code	Therapeutic category	Formulation	Region	Development stage
T-705	Anti-COVID-19 drug	Oral	Japan	Submitted an application for permission
			U.S.A.	PⅡ
	Severe fever with thrombocytopenia syndrome virus drug		Japan	PⅢ
T-817MA	Alzheimer's disease drug	Oral	U.S.A.	PⅡ
			Japan	PⅡ
			Europe	PⅡ
	Functional recovery after stroke（Promoting the effect of rehabilitation）		Japan	PⅡ
T-4288	New fluoroketolide antibacterial drug	Oral	Japan	Submitted an application for permission
FF-10501	Myelodysplastic syndrome drug	Oral	Japan	PⅠ
			U.S.A.	PⅡ
FF-10502	Advanced/recurrent solid cancer drug	Injection	U.S.A.	PⅡ
FF-21101	Bio Advanced/recurrent solid cancer drug (Armed antibody)	Injection	U.S.A.	PⅠ/Ⅱa
			Japan	PⅠ
F-1311	Diagnostic drug for prostate cancer (Radiopharmaceuticals)	Injection	Japan	PⅡ
FF-10101	Acute Myeloid Leukemia (AML) drug	Oral	U.S.A.	PⅠ
F-1515	Anti-tumor (neuroendocrine tumors) drug (Radiopharmaceuticals)	injection	Japan	Submitted an application for permission
FF-10832	Advanced solid cancer drug（Gemcitabine liposome）	Injection	U.S.A.	PⅠ
FF-10850	Advanced solid cancer drug（Topotecan liposome）	Injection	U.S.A.	PⅠ
F-1614	Anti-tumor (pheochromocytoma) drug (Radiopharmaceuticals)	Injection	Japan	PⅡ

Related Information

FUJIFILM Holdings — Investor Relations
https://ir.fujifilm.com/en/investors.html

FUJIFILM Holdings Integrated Report 2020
https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html

IR Events Materials
https://ir.fujifilm.com/en/investors/ir-materials/presentations.html

Business Activities of FUJIFILM Group
https://ir.fujifilm.com/en/investors/value/business.html

Global Branding Campaign: NEVER STOP
https://brand.fujifilm.com/neverstop/en/

Fujifilm's Response to the COVID-19 Pandemic
https://brand.fujifilm.com/covid19/

FUJIFILM

Value from Innovation

At Fujifilm, we are continuously innovating — creating new technologies, products and services that inspire and excite people everywhere.
Our goal is to empower the potential and expand the horizons of tomorrow's businesses and lifestyles.

FUJIFILM Holdings Corporation
Corporate Communications Div.
https://holdings.fujifilm.com/en